Fosfomycin calcium

Fosfomycin calcium (CAS No.: 26016-98-8) is a broad-spectrum, bactericidal antibiotic that targets the early stage of bacterial cell wall biosynthesis by irreversibly inhibiting key enzymatic steps involved in peptidoglycan formation, thereby disrupting cell wall integrity and leading to bacterial cell death. As a phosphonic acid-derived antimicrobial agent, it demonstrates the ability to penetrate the blood-brain barrier and exhibits robust in vitro and in vivo activity against a wide spectrum of Gram-positive and Gram-negative pathogens, including clinically relevant multidrug-resistant, extensively drug-resistant, and pan-drug-resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and resistant Streptococcus pneumoniae, as well as organisms like Salmonella and Pseudomonas aeruginosa, typically with activity observed in the low micromolar to microgram-per-milliliter range depending on the species and assay conditions. Its unique mechanism of action and lack of cross-resistance with many other antibiotic classes make it a valuable tool compound for studying bacterial cell wall synthesis pathways, resistance mechanisms, and antimicrobial susceptibility in both cell-based and animal infection models. Fosfomycin calcium is widely utilized in antibacterial drug discovery and microbiological research, particularly in the evaluation of novel therapeutic strategies targeting resistant pathogens, with experimental concentrations or dosing regimens varying according to specific study designs and biological systems.